CTRI/2023/04/051474尚未招募3 期
Standard medical therapy plus rifaximin vs. standard medical therapy alone for the management of sarcopenia in patients with cirrhosis : A PILOT Randomized Controlled Trial.
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- AIIMS
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients with cirrhosis (Child A and B) and sarcopenia
排除标准
- •1.Patients with history of overt hepatic encephalopathy (HE) or those who develop HE during treatment
- •2.Patients with sepsis, active GI bleed or acute kidney injury
- •3.Known cases of hepatocellular carcinoma
- •4.Any severe chronic illness including congestive heart failure, chronic kidney disease, neuromuscular disorders or HIV
- •5.History of any chronic drug intake such as corticosteroids
- •6.History of drugs postulated to increase muscle mass such as testosterone, growth hormone, anabolic steroids
研究者
相似试验
尚未招募
不适用
Standard medical therapy plus rifaximin vs. standard medical therapy alone for the management of sarcopenia in patients with cirrhosisCTRI/2022/03/040923AIIMS New Delhi
已完成
不适用
ROLE OF RIFAXIMIN ON FRAILTY (MUSCLE WEAKNESS) IN DECOMPENSATED CIRRHOSIS (CHRONIC LIVER DISEASE)CTRI/2023/01/048824PGIMER100
尚未招募
Unknown
The effect of Rifaximin (an antibiotic drug commonly used in liver failure patients) and standard medical therapy vs standard medical therapy alone on myosteatosis (fat deposition in abdominal muscles), in patients with decompensated cirrhosis- a randomized controlled trialCTRI/2024/07/069984PGIMER, CHANDIGARH
已完成
不适用
A study to compare effects of Tablet Rifaximin alone and in combination with Tablet Norfloxacin for prevention of re-occuring bacterial infection of abdominal fluid and brain function abnormality due to liver disease.CTRI/2021/09/036321Pt BD Sharma PGIMS Rohtak49
招募中
不适用
Efficacy and safety of Rifaximin for the treatment of liver cirrhosis with covert hepatic encephalopathyiver cirrhosisJPRN-UMIN000044657Wakayama Medical University40